Loading clinical trials...

Ketamine and Lidocaine Infusion in Refractory Chronic Migraine | Clinical Trials | Clareo Health

NOT_YET_RECRUITINGEARLY_PHASE1

Ketamine and Lidocaine Infusion in Refractory Chronic Migraine

Ketamine and Lidocaine Infusion for Refractory Chronic Migraine: Comparative Study

NCT06935552•Assiut University

View on ClinicalTrials.gov

Summary

Ketamine and lidocaine infusion for refractory chronic migraine: Comparative Study

Eligibility

Age

18 - 60 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. medically stable outpatients with confirmed diagnosis of refractory chronic migraine according to American Headache society
•2. Are reliable and willing to make themselves available for the duration of the study and are willing to follow up.
•3. Men or women older than 18years of age.
•4. clear written informed consent from each participant in the trial.
•5. Adult patients with refractory migraine or refractory chronic migraine defined according to the American headache society

Exclusion Criteria

•1. Pregnancy, active psychosis, liver disease, uncontrolled cardiac disease or cardiac rhythm abnormalities
•2. presence of clinically significant medical or psychiatric condition that may increase the risk associated with the study
•3. participation in any other type of medical research that may interfere with the interpretation of the study.
•4. patients with hemocoagulation disorders, local infection or those who refused to consent

Key Dates

Start Date

June 1, 2025

Primary Completion Date

November 1, 2026

Completion Date

December 1, 2026

Last Updated

April 20, 2025

Enrollment

ESTIMATED participants

Conditions

Refractory Chronic Migraine

Interventions

Ketamine infusion

DRUG

Lidocaine Intravenous Infusion

DRUG

Dextrose 5% in water

DRUG

Contacts

AbdElRahman Mohamed Mohamed

CONTACT

+201066586931 hmdmhmmdl1692@gmail.com

A Feasibility Clinical Trial to Evaluate High Frequency Spinal Cord Stimulation for the Treatment of Patients With Chronic Migraine

NCT01653340

Refractory Chronic Migraine

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 20, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions